UK market entry decision model for medical devices: four variables and obligations

1. Key takeaways

The British route for any product can be derived from four variables: first, certificate status (no certificate / MDD-AIMDD / MDR-IVDR / approvals from Australia, Canada or the United States); second, product classification (Class I / IIa / IIb / III / AIMD / IVD levels); third, category (routine / custom-made / system or procedure pack); and fourth, sales territory (GB only / NI only / both). Once the four variables are fixed for a given product, the route and the obligations follow deterministically, and the three standing obligations of UKRP, MHRA registration and PMS apply in every combination of the variables, with no exemptions for any of them.

The value of the model is that it converts a large, constantly changing rulebook into a small, stable set of questions that can be answered for each product without legal interpretation. Sales, supply chain and finance teams can collect the four variable values, the regulatory function can derive the consequences, and disputes about market entry sequencing can be settled by reference to the model rather than by escalation. It also exposes scale: the number of distinct variable combinations across a portfolio is usually far smaller than the number of products, which makes programme planning tractable.

A worked illustration shows the model’s economy. A product with an MDR certificate, Class IIa classification, routine category and GB-only sales resolves in seconds: reg 19C carries it into the market, a UKRP is appointed, MHRA registration follows under the applicable provision, and PMS duties attach without any further choices being made. Change only the territory variable to GB plus NI, and the card now additionally carries the EU-side registration and representative requirements that the second regime imposes. Nothing about the product changed, yet the workload roughly doubled, which is exactly the kind of consequence the four-variable frame makes explicit before contracts are signed.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): reg 1ZA, reg 19B, reg 19C, reg 30A, reg 44ZA and reg 44ZB (routes); reg 7A, reg 19, reg 21A, reg 21B, reg 33A and reg 44 (registration); Part 4A regs 44ZC to 44ZR (PMS).
• SI 2023/627 (made on 9 June 2023) reg 4; SI 2024/1368 (in force on 16 June 2025); SI 2026/197 (in force on 1 April 2026, reg 3).
• GOV.UK news announcement (21 October 2026): the policy direction of long-term recognition.

3. Expert insights

Insight one: of the four duty groups, only the route is optional. Classification, the UKRP, registration and PMS form the obligation layer and must be performed whichever route is taken. The only variable in the route layer is by what evidence conformity is demonstrated. This structure sets the floor of workload for any British project: even the cheapest entry route leaves the entire obligation layer intact. Budgeting exercises that assume a lighter route lightens the whole programme therefore understate the true cost, and the error compounds across a portfolio rather than averaging out.

Insight two: the cost centre is moving from premarket to postmarket. Of the three instruments changed in the last two years, two land on the postmarket and maintenance side: Part 4A, in force since 16 June 2025, brings the PMS system and periodic reporting duties; and SI 2026/197, in force since 1 April 2026, introduces an annual maintenance fee of £300 per GMDN Level 2 category per year. Holding a British registration long-term already costs significantly more than obtaining it. Portfolio decisions made on premarket cost alone will systematically over-favour breadth, because the recurring fee scales with the number of GMDN Level 2 categories a company touches, not with the number of products.

Insight three: territory is the most commonly underestimated cost variable. Choosing GB plus NI means running the UK MDR 2002 and the EU MDR/IVDR as two parallel regimes, and from 28 May 2026 non-custom devices in NI must be registered in EUDAMED while GB manufacturers must appoint an authorised representative within the EU or Northern Ireland. The two-regime option therefore doubles not only the assessment work but also the standing infrastructure: two representatives, two registers, two sets of periodic reporting rhythms. For narrow product lines the incremental market may not carry that overhead, which is precisely the calculation the model is designed to make visible before commitments are made.

4. Practical recommendations

GRZAN recommends turning the four variables into a decision matrix that outputs one card per SKU, recording: the applicable transition provision, the expiry point, whether a UK approved body is needed, the UKRP requirement, the registration provision, the number of fee-bearing category years, and the PMSR/PSUR frequency. The card format matters: because each card is small and self-contained, it can be attached directly to commercial quotations and to internal production scheduling, so the regulatory position travels with the product instead of living only in a compliance document nobody opens.

Cards should be regenerated whenever any of the four variables changes or a relevant instrument is amended, and each regeneration should be dated. The set of cards then doubles as the audit trail of the market entry programme, showing what the company believed at each point in time and on which legal basis, which is exactly the record an inspector or an acquirer will ask for.

The model also disciplines conversations with distributors. When a distributor requests entry into a territory the card does not cover, the request is answered by changing a variable and regenerating the card, rather than by an improvised exception. Over time the accumulated cards show which variable changes recur, and that pattern is useful commercially: a territory repeatedly requested but repeatedly declined is a candidate for a deliberate investment decision, made once, with the full obligation layer priced in, instead of being relitigated deal by deal.

5. Verification checklist

• □ The four variables have been fixed for every SKU
• □ A route and obligation card has been produced for every SKU
• □ Annual fees have been estimated (by the number of GMDN Level 2 categories)
• □ PMSR/PSUR frequencies and owners have been confirmed
• □ The territory variable covers the EUDAMED and authorised representative requirements

Regulatory information verified as of 29 October 2026.

• Appointment of a UK responsible person (UKRP) and support for signing the letter of authorisation
• MHRA registration (DORS): end-to-end filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee estimates
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) options
• Post-market surveillance (PMS) system build, PMSR/PSUR preparation and vigilance reporting
• Emergency handling of serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory change and compliance gap assessments

GRZAN supports manufacturers entering the United Kingdom with UKCA registration pathways and classification strategy, from first route analysis through to registration and post-market obligations. For a structured review of your product portfolio, contact info@grzanglobal.com.